| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Assessing the performance of prediction models: a framework for traditional and novel measures.
|
Epidemiology
|
2010
|
14.07
|
|
2
|
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study.
|
Lancet Oncol
|
2006
|
8.61
|
|
3
|
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
|
Cancer
|
2010
|
5.22
|
|
4
|
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
|
Nat Rev Cancer
|
2008
|
4.15
|
|
5
|
Empirical study of data sharing by authors publishing in PLoS journals.
|
PLoS One
|
2009
|
4.09
|
|
6
|
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
|
J Clin Oncol
|
2009
|
3.74
|
|
7
|
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
|
J Clin Oncol
|
2007
|
3.72
|
|
8
|
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence.
|
J Natl Cancer Inst
|
2007
|
3.70
|
|
9
|
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
|
J Clin Oncol
|
2008
|
3.50
|
|
10
|
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers.
|
BMJ
|
2010
|
3.38
|
|
11
|
Low annual caseloads of United States surgeons conducting radical prostatectomy.
|
J Urol
|
2009
|
3.04
|
|
12
|
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
|
Cancer
|
2010
|
2.90
|
|
13
|
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.
|
Ann Intern Med
|
2015
|
2.71
|
|
14
|
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories.
|
J Urol
|
2008
|
2.57
|
|
15
|
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers.
|
Trials
|
2010
|
2.54
|
|
16
|
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.
|
J Urol
|
2006
|
2.50
|
|
17
|
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
|
BMC Med
|
2008
|
2.39
|
|
18
|
Prognostic significance of location of positive margins in radical prostatectomy specimens.
|
Urology
|
2007
|
2.23
|
|
19
|
Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy.
|
Eur Urol
|
2007
|
2.19
|
|
20
|
A simple schema for informed decision making about prostate cancer screening.
|
Ann Intern Med
|
2014
|
2.12
|
|
21
|
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
|
J Clin Oncol
|
2009
|
2.05
|
|
22
|
Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care.
|
BMJ
|
2004
|
2.03
|
|
23
|
Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm.
|
BJU Int
|
2006
|
2.00
|
|
24
|
Variations among experienced surgeons in cancer control after open radical prostatectomy.
|
J Urol
|
2010
|
1.93
|
|
25
|
Decision curve analysis: a discussion.
|
Med Decis Making
|
2008
|
1.87
|
|
26
|
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
|
Eur Urol
|
2011
|
1.85
|
|
27
|
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
|
J Clin Oncol
|
2012
|
1.82
|
|
28
|
Prostate cancer: estimating the benefits of PSA screening.
|
Nat Rev Urol
|
2009
|
1.76
|
|
29
|
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
|
Cancer
|
2006
|
1.75
|
|
30
|
Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates.
|
J Urol
|
2010
|
1.66
|
|
31
|
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience.
|
Eur Urol
|
2008
|
1.66
|
|
32
|
Risk-based prostate cancer screening.
|
Eur Urol
|
2011
|
1.64
|
|
33
|
Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study.
|
Cancer
|
2013
|
1.62
|
|
34
|
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer.
|
Cancer
|
2008
|
1.62
|
|
35
|
Massage therapy for symptom control: outcome study at a major cancer center.
|
J Pain Symptom Manage
|
2004
|
1.60
|
|
36
|
Critical review of prostate cancer predictive tools.
|
Future Oncol
|
2009
|
1.57
|
|
37
|
Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?
|
Cancer
|
2006
|
1.53
|
|
38
|
Immediate effects of dry needling and acupuncture at distant points in chronic neck pain: results of a randomized, double-blind, sham-controlled crossover trial.
|
Pain
|
2002
|
1.53
|
|
39
|
A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons.
|
BJU Int
|
2013
|
1.51
|
|
40
|
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy.
|
Eur Urol
|
2011
|
1.50
|
|
41
|
Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy.
|
Eur Urol
|
2012
|
1.50
|
|
42
|
Is it necessary to remove the seminal vesicles completely at radical prostatectomy? decision curve analysis of European Society of Urologic Oncology criteria.
|
J Urol
|
2008
|
1.50
|
|
43
|
A systematic review of the volume-outcome relationship for radical prostatectomy.
|
Eur Urol
|
2013
|
1.48
|
|
44
|
Assessing the incremental value of diagnostic and prognostic markers: a review and illustration.
|
Eur J Clin Invest
|
2011
|
1.46
|
|
45
|
Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer.
|
J Clin Oncol
|
2012
|
1.44
|
|
46
|
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
|
World J Urol
|
2011
|
1.42
|
|
47
|
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer.
|
Cancer J
|
2006
|
1.42
|
|
48
|
Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer.
|
Cancer Res
|
2008
|
1.42
|
|
49
|
Net reclassification improvement and decision theory.
|
Stat Med
|
2009
|
1.41
|
|
50
|
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
|
J Urol
|
2007
|
1.41
|
|
51
|
Reducing systematic review to a cut and paste.
|
Forsch Komplementmed
|
2010
|
1.40
|
|
52
|
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
|
BJU Int
|
2013
|
1.39
|
|
53
|
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.
|
Clin Cancer Res
|
2007
|
1.38
|
|
54
|
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
|
Cancer Prev Res (Phila)
|
2010
|
1.35
|
|
55
|
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
|
J Clin Oncol
|
2006
|
1.32
|
|
56
|
Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.
|
Eur Urol
|
2010
|
1.30
|
|
57
|
Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer.
|
Cancer
|
2009
|
1.29
|
|
58
|
Tumor markers in prostate cancer I: blood-based markers.
|
Acta Oncol
|
2011
|
1.28
|
|
59
|
Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial.
|
J Clin Oncol
|
2010
|
1.27
|
|
60
|
Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy.
|
Cancer
|
2011
|
1.26
|
|
61
|
Making raw data more widely available.
|
BMJ
|
2011
|
1.25
|
|
62
|
Fellowship training as a modifier of the surgical learning curve.
|
Acad Med
|
2010
|
1.24
|
|
63
|
Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results?
|
J Clin Oncol
|
2011
|
1.24
|
|
64
|
Acupuncture for tension-type headache: a multicentre, sham-controlled, patient-and observer-blinded, randomised trial.
|
J Headache Pain
|
2007
|
1.22
|
|
65
|
The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer.
|
J Urol
|
2006
|
1.20
|
|
66
|
Susceptibility loci associated with prostate cancer progression and mortality.
|
Clin Cancer Res
|
2010
|
1.19
|
|
67
|
High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care.
|
J Clin Oncol
|
2005
|
1.18
|
|
68
|
Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.18
|
|
69
|
Statistical methods to correct for verification bias in diagnostic studies are inadequate when there are few false negatives: a simulation study.
|
BMC Med Res Methodol
|
2008
|
1.14
|
|
70
|
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.
|
J Clin Oncol
|
2007
|
1.13
|
|
71
|
Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures.
|
Med Decis Making
|
2013
|
1.13
|
|
72
|
Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility.
|
Eur Urol
|
2013
|
1.12
|
|
73
|
Does the net reclassification improvement help us evaluate models and markers?
|
Ann Intern Med
|
2014
|
1.12
|
|
74
|
Prediction models: revolutionary in principle, but do they do more good than harm?
|
J Clin Oncol
|
2011
|
1.10
|
|
75
|
Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial.
|
Cancer
|
2003
|
1.09
|
|
76
|
Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy.
|
Urology
|
2007
|
1.08
|
|
77
|
The surgical learning curve for artificial urinary sphincter procedures compared to typical surgeon experience.
|
Eur Urol
|
2011
|
1.06
|
|
78
|
Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
|
Chest
|
2007
|
1.01
|
|
79
|
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects.
|
J Cancer Res Clin Oncol
|
2009
|
1.01
|
|
80
|
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
|
World J Urol
|
2011
|
1.00
|
|
81
|
Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship.
|
BMC Med Inform Decis Mak
|
2010
|
0.98
|
|
82
|
Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer.
|
BJU Int
|
2006
|
0.98
|
|
83
|
Prostate Cancer Early Detection, Version 2.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.98
|
|
84
|
Characteristics of acupuncture treatment associated with outcome: an individual patient meta-analysis of 17,922 patients with chronic pain in randomised controlled trials.
|
PLoS One
|
2013
|
0.98
|
|
85
|
Placebo controls in randomized trials of acupuncture.
|
Eval Health Prof
|
2002
|
0.97
|
|
86
|
Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
|
Clin Chem
|
2006
|
0.95
|
|
87
|
Sixty years of CA: a cancer journal for clinicians.
|
CA Cancer J Clin
|
2010
|
0.95
|
|
88
|
Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy.
|
Cancer
|
2006
|
0.95
|
|
89
|
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
|
World J Urol
|
2012
|
0.94
|
|
90
|
Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice.
|
Neuron Glia Biol
|
2004
|
0.94
|
|
91
|
Comparison of models to predict clinical failure after radical prostatectomy.
|
Cancer
|
2009
|
0.92
|
|
92
|
Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.
|
J Natl Cancer Inst
|
2012
|
0.92
|
|
93
|
Cutpoints in clinical chemistry: time for fundamental reassessment.
|
Clin Chem
|
2008
|
0.91
|
|
94
|
Pelvic lymph node dissection for patients with elevated risk of lymph node invasion during radical prostatectomy: comparison of open, laparoscopic and robot-assisted procedures.
|
J Endourol
|
2011
|
0.89
|
|
95
|
Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function.
|
J Urol
|
2006
|
0.89
|
|
96
|
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
|
Int J Cancer
|
2006
|
0.87
|
|
97
|
Re: Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.
|
J Natl Cancer Inst
|
2011
|
0.87
|
|
98
|
Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years.
|
Int J Cancer
|
2013
|
0.86
|
|
99
|
Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram.
|
Urology
|
2009
|
0.86
|
|
100
|
Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance.
|
J Urol
|
2007
|
0.85
|
|
101
|
The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop.
|
Transfusion
|
2012
|
0.85
|
|
102
|
A safety and efficacy pilot study of acupuncture for the treatment of chronic lymphoedema.
|
Acupunct Med
|
2011
|
0.85
|
|
103
|
Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function.
|
BJU Int
|
2008
|
0.85
|
|
104
|
Anatomy of accessory pudendal arteries in laparoscopic radical prostatectomy.
|
J Urol
|
2005
|
0.83
|
|
105
|
Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis.
|
Cancer
|
2011
|
0.83
|
|
106
|
Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion.
|
J Oncol Pract
|
2012
|
0.82
|
|
107
|
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
|
BJU Int
|
2010
|
0.82
|
|
108
|
Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
|
J Natl Cancer Inst
|
2011
|
0.82
|
|
109
|
Prostate cancer: why is PSA velocity such a sticky concept?
|
Nat Rev Urol
|
2013
|
0.82
|
|
110
|
Primer: using decision analysis to improve clinical decision making in urology.
|
Nat Clin Pract Urol
|
2006
|
0.82
|
|
111
|
Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
|
Int J Cancer
|
2011
|
0.81
|
|
112
|
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
|
Int J Cancer
|
2009
|
0.81
|
|
113
|
Urological cancer: Time for another rethink on prostate cancer screening.
|
Nat Rev Clin Oncol
|
2011
|
0.81
|
|
114
|
Complementary and alternative therapies.
|
Urol Clin North Am
|
2003
|
0.81
|
|
115
|
Editorial comment.
|
Urology
|
2011
|
0.80
|
|
116
|
Incorporating predictions of individual patient risk in clinical trials.
|
Urol Oncol
|
2004
|
0.80
|
|
117
|
Risk of cancer-specific mortality following recurrence after radical nephroureterectomy.
|
Ann Surg Oncol
|
2012
|
0.78
|
|
118
|
Predictors of survival in patients with disease recurrence after radical nephroureterectomy.
|
BJU Int
|
2014
|
0.78
|
|
119
|
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
|
Clin Chem Lab Med
|
2012
|
0.78
|
|
120
|
The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk.
|
Ann Intern Med
|
2015
|
0.78
|
|
121
|
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.
|
Eur Urol
|
2013
|
0.76
|
|
122
|
Editorial comment on: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.
|
Eur Urol
|
2008
|
0.76
|
|
123
|
The continuing role of prostate-specific antigen as a marker for localized prostate cancer: 'do not throw the baby out with the bath water'.
|
BJU Int
|
2009
|
0.76
|
|
124
|
PSA is dead, long live PSA.
|
Eur Urol
|
2011
|
0.75
|
|
125
|
Soy: an anticancer agent in wide use despite some troubling data.
|
Cancer Invest
|
2003
|
0.75
|
|
126
|
New Prognostic Markers: The Pathway from Research to Clinical Practice.
|
Grand rounds Urol
|
2009
|
0.75
|
|
127
|
A personalized automated messaging system to improve adherence to prostate cancer screening: research protocol.
|
JMIR Res Protoc
|
2012
|
0.75
|
|
128
|
In reply.
|
JAMA Intern Med
|
2013
|
0.75
|
|
129
|
Radical prostatectomy versus observation for prostate cancer.
|
N Engl J Med
|
2012
|
0.75
|
|
130
|
Informed decision making about prostate cancer screening.
|
Ann Intern Med
|
2015
|
0.75
|
|
131
|
Editorial comment.
|
J Urol
|
2012
|
0.75
|
|
132
|
Book review: Offit P. Do You Believe in Magic? HarperCollins, New York, 2013 Offit P . Do You Believe in Magic? HarperCollins , New York , 2013 .
|
Clin Trials
|
2014
|
0.75
|
|
133
|
Reply to Re: The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.
|
Urology
|
2016
|
0.75
|